|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
|
DE68921982D1
(en)
|
1988-06-14 |
1995-05-04 |
Cetus Oncology Corp |
COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
|
DE69029036T2
(en)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
SPECIFIC REAGENTS FOR AIDS THERAPY
|
|
ATE139258T1
(en)
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
GENERATION OF XENOGENE ANTIBODIES
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
ATE158615T1
(en)
|
1990-03-20 |
1997-10-15 |
Univ Columbia |
CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5219837A
(en)
|
1990-06-21 |
1993-06-15 |
Trustees Of The University Of Pennsylvania |
Method of stimulating myelination of cells
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
AU667460B2
(en)
|
1990-10-05 |
1996-03-28 |
Medarex, Inc. |
Targeted immunostimulation with bispecific reagents
|
|
US5858725A
(en)
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
|
EP0557300B1
(en)
|
1990-10-29 |
1997-11-19 |
Chiron Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
ATE218889T1
(en)
|
1990-11-09 |
2002-06-15 |
Stephen D Gillies |
CYTOKINE IMMUNOCONJUGATES
|
|
AU665758B2
(en)
|
1991-04-26 |
1996-01-18 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
US5843749A
(en)
|
1991-07-26 |
1998-12-01 |
Regeneron Pharmaceuticals, Inc. |
Ehk and Ror tyrosine kinases
|
|
WO1993017715A1
(en)
|
1992-03-05 |
1993-09-16 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
|
US7473423B2
(en)
|
1994-04-29 |
2009-01-06 |
Mayo Foundation For Medical Education And Research |
Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
|
AU722668B2
(en)
|
1994-12-30 |
2000-08-10 |
King's College London |
Methods for producing immunoglobulins containing protection proteins in plants and their use
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0833911B1
(en)
|
1995-06-07 |
2004-05-12 |
Ortho Pharmaceutical Corporation |
Cdr-grafted anti-tissue factor antibodies and methods of use thereof
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
AU6582698A
(en)
|
1997-03-19 |
1998-10-12 |
Johns Hopkins University, The |
Therapeutic uses of grip and grip-related molecules
|
|
US6287569B1
(en)
|
1997-04-10 |
2001-09-11 |
The Regents Of The University Of California |
Vaccines with enhanced intracellular processing
|
|
US7435549B1
(en)
|
1997-11-17 |
2008-10-14 |
Micromet Ag |
Method of identifying binding site domains that retain the capacity of binding to an epitope
|
|
ATE512225T1
(en)
|
1998-04-03 |
2011-06-15 |
Chugai Pharmaceutical Co Ltd |
HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND METHOD FOR CONSTRUCTING SUCH HUMANIZED ANTIBODY.
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
US6605709B1
(en)
|
1999-04-09 |
2003-08-12 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
|
|
EP1267926A2
(en)
|
2000-03-17 |
2003-01-02 |
Millennium Pharmaceuticals, Inc. |
Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
|
|
MXPA02012434A
(en)
|
2000-06-16 |
2004-09-06 |
Cambridge Antibody Tech |
Antibodies that immunospecifically bind to blys.
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7214786B2
(en)
|
2000-12-14 |
2007-05-08 |
Kovalic David K |
Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
|
|
US20140072979A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
|
US20140072980A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
|
DE60211329T2
(en)
|
2001-01-16 |
2007-05-24 |
Regeneron Pharmaceuticals, Inc. |
ISOLATION OF SEPARATED PROTEINS EXPRESSING CELLS
|
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
|
US20030020733A1
(en)
|
2001-07-24 |
2003-01-30 |
Yin Memphis Zhihong |
Computer display having selective area magnification
|
|
EP1425694A2
(en)
|
2001-08-03 |
2004-06-09 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
|
EP2383290B1
(en)
|
2001-08-23 |
2019-05-08 |
Rsr Limited |
Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto
|
|
CA2462653C
(en)
|
2001-11-07 |
2016-06-07 |
Aya Jakobovits |
Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
|
|
EP3960855A1
(en)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing proteins
|
|
US7381801B2
(en)
|
2002-02-13 |
2008-06-03 |
Ludwig Institute For Cancer Research |
Chimerized GM-CSF antibodies
|
|
US7314974B2
(en)
|
2002-02-21 |
2008-01-01 |
Monsanto Technology, Llc |
Expression of microbial proteins in plants for production of plants with improved properties
|
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
|
HUE025101T2
(en)
|
2002-04-26 |
2016-02-29 |
Genentech Inc |
Non-affinity purification of proteins
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
WO2004009805A1
(en)
|
2002-07-19 |
2004-01-29 |
Japan Science And Technology Agency |
Novel process for producing antibody enzyme, novel antibody enzyme and utilization thereof
|
|
DK1551876T3
(en)
|
2002-10-16 |
2011-06-14 |
Purdue Pharma Lp |
Antibodies that bind to cell associates approximately 125 / 0722P and methods for their use
|
|
WO2004068931A2
(en)
|
2003-02-07 |
2004-08-19 |
Protein Design Labs Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
|
KR20060015602A
(en)
|
2003-05-31 |
2006-02-17 |
마이크로메트 에이지 |
Pharmaceutical composition comprising a bispecific antibody against EVCA
|
|
US7569389B2
(en)
|
2004-09-30 |
2009-08-04 |
Ceres, Inc. |
Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
|
|
WO2005035753A1
(en)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
KR20120125634A
(en)
|
2003-10-16 |
2012-11-16 |
마이크로메트 에이지 |
Multispecific deimmunized cd3-binders
|
|
US7612179B2
(en)
|
2003-11-28 |
2009-11-03 |
Astrazeneca Ab |
antibodies binding to a C-terminal fragment of apoliopoprotein E
|
|
US20050191293A1
(en)
|
2003-12-10 |
2005-09-01 |
Shrikant Deshpande |
IP-10 antibodies and their uses
|
|
AU2005206536B2
(en)
|
2004-01-16 |
2010-09-02 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
KR20060131892A
(en)
|
2004-02-16 |
2006-12-20 |
마이크로메트 에이지 |
Less Immunogenic Binding Molecules
|
|
EP1716181B1
(en)
|
2004-02-19 |
2009-12-16 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
US7192709B2
(en)
|
2004-03-15 |
2007-03-20 |
Digigenomics Co., Ltd. |
Methods for identification, assessment, prevention, and therapy of cancer
|
|
US7504086B2
(en)
|
2004-03-31 |
2009-03-17 |
Canon Kabushiki Kaisha |
Structure and method for releasing substance therefrom
|
|
CA2563333A1
(en)
*
|
2004-04-06 |
2005-10-27 |
The Regents Of The University Of California |
Orphan receptor tyrosine kinase as a target in breast cancer
|
|
CN101495512A
(en)
|
2004-04-22 |
2009-07-29 |
弗劳恩农场主协会应用研究开发E.V. |
A diabody which specifically binds streptococcus surface antigen I/II and methods of use thereof
|
|
US7763249B2
(en)
|
2004-04-27 |
2010-07-27 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Human anti-amyloid β peptide antibody and fragment of said antibody
|
|
UY28886A1
(en)
|
2004-05-10 |
2005-12-30 |
Boehringer Ingelheim Int |
ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18
|
|
MXPA06014354A
(en)
|
2004-06-09 |
2007-02-19 |
Genentech Inc |
Method of treating granuloma annulare or sarcoid.
|
|
BRPI0514478A
(en)
|
2004-08-16 |
2008-06-17 |
Cropdesign Nv |
method for enhancing plant growth characteristics, plants, construction, method for producing a transgenic plant, transgenic plant, collectable parts, and uses of a nucleic acid / gene encoding rna binding protein or variant thereof or use of an rna binding protein or homologue thereof, an rbp1 or variant thereof or use of an rbp1 polypeptide or homologue thereof and an rna binding protein or variant thereof or use of an rbp1 or variant thereof
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP2008520186A
(en)
|
2004-10-01 |
2008-06-19 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Novel antibody against mammalian EAG1 ion channel protein
|
|
WO2006067122A2
(en)
|
2004-12-20 |
2006-06-29 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
|
DK1848744T3
(en)
|
2005-01-27 |
2012-03-19 |
Novimmune Sa |
Human anti-interferon gamma antibodies and methods for their use
|
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
|
CN101870730A
(en)
|
2005-03-31 |
2010-10-27 |
生物医药股份有限公司 |
Anti-CD-20 monoclonal antibody
|
|
JP5004154B2
(en)
|
2005-04-06 |
2012-08-22 |
一般財団法人化学及血清療法研究所 |
Recombinant anti-botulinum neurotoxin antibody
|
|
PL1874818T3
(en)
|
2005-04-22 |
2011-09-30 |
Lilly Co Eli |
Tgf beta 1 specific antibodies
|
|
WO2006138005A2
(en)
|
2005-05-10 |
2006-12-28 |
Monsanto Technology, Llc |
Genes and uses for plant improvement
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
HUE032131T2
(en)
|
2005-08-31 |
2017-09-28 |
Merck Sharp & Dohme |
Engineered anti-il-23 antibodies
|
|
WO2008103849A2
(en)
*
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
|
ES2402576T3
(en)
|
2005-11-14 |
2013-05-06 |
Bioren, Inc. |
Antibody ultrahumanization by generation and selection of predicted mature cdr cohort and blast libraries
|
|
DK1989302T3
(en)
|
2006-02-14 |
2018-07-23 |
Bp Corp North America Inc |
XYLANASES, NUCLEIC ACID CODING THEM AND PROCEDURES FOR THEIR PREPARATION AND USE
|
|
JPWO2007102200A1
(en)
|
2006-03-07 |
2009-07-23 |
国立大学法人大阪大学 |
Anti-CD20 monoclonal antibody
|
|
WO2007146957A2
(en)
|
2006-06-13 |
2007-12-21 |
Irm Llc |
Ror1 as a therapeutic target for lung cancer
|
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
|
EA201201533A1
(en)
|
2006-08-18 |
2014-11-28 |
Новартис Аг |
PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
|
|
EA018260B1
(en)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Antibodies to human delta-like ligand 4 (dll4) and use thereof
|
|
AU2007325872B2
(en)
|
2006-11-08 |
2012-12-13 |
Macrogenics West, Inc. |
TES7 and antibodies that bind thereto
|
|
FR2909092B1
(en)
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
NEW ANTI-PROLIFERATION ANTIBODIES
|
|
WO2008076868A2
(en)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
|
|
JP2010512791A
(en)
|
2006-12-22 |
2010-04-30 |
シェーリング コーポレイション |
Antibody to CD200R
|
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
ATE540313T1
(en)
|
2007-05-03 |
2012-01-15 |
Regeneron Pharma |
IDENTIFICATION OF GERMINAL EMBRYONIC STEM CELLS
|
|
BRPI0721707A2
(en)
|
2007-05-17 |
2013-01-15 |
Genentech Inc |
crystal structures of neuropillin fragments and neuropillin-antibody complexes
|
|
CA2691734A1
(en)
|
2007-07-04 |
2009-01-08 |
Forerunner Pharma Research Co., Ltd. |
Anti-muc17 antibody
|
|
US8299318B2
(en)
|
2007-07-05 |
2012-10-30 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
|
AU2008278803A1
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binging agents directed to KDR and uses thereof - 035
|
|
EP2186892A1
(en)
|
2007-09-06 |
2010-05-19 |
Osaka University |
Anti-cd20 monoclonal antibodies
|
|
US8362325B2
(en)
|
2007-10-03 |
2013-01-29 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
|
SI2211904T1
(en)
|
2007-10-19 |
2016-12-30 |
Seattle Genetics, Inc. |
Cd19 binding agents and uses thereof
|
|
US8715941B2
(en)
|
2007-11-16 |
2014-05-06 |
Arca Biopharma, Inc. |
Antibodies to LRP6
|
|
CA2708532C
(en)
|
2007-12-05 |
2018-06-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il31ra antibody and use thereof
|
|
SG186656A1
(en)
|
2007-12-14 |
2013-01-30 |
Bristol Myers Squibb Co |
Binding molecules to the human ox40 receptor
|
|
US8147836B2
(en)
|
2007-12-17 |
2012-04-03 |
Dyax Corp. |
Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
|
|
AU2008343855B2
(en)
|
2007-12-21 |
2013-08-15 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
|
KR101642846B1
(en)
|
2007-12-26 |
2016-07-26 |
백시넥스 인코포레이티드 |
Anti-C35 antibody combination therapies and methods
|
|
BRPI0907648B1
(en)
|
2008-01-29 |
2022-01-11 |
Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine |
ISOLATED HUMANIZED ANTIBODY, USES OF AN ANTIBODY, METHODS FOR PREPARING AN ANTIBODY, FOR GENERATING IMMUNOREATIVE ANTIBODIES WITH SLC34A2, AND FOR SCREENING OR IDENTIFYING AGENTS OR COMPOUNDS THAT MODULATE SLC34A2, COMPOSITIONS, ISOLATED NUCLEIC ACID, AND, HOST MICROORGANISM
|
|
WO2009099580A2
(en)
|
2008-02-05 |
2009-08-13 |
Monsanto Technology, Llc |
Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
|
|
AR070316A1
(en)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
|
|
CN104548091A
(en)
|
2008-02-11 |
2015-04-29 |
治疗科技公司 |
Monoclonal antibodies for tumor treatment
|
|
EP2262529A4
(en)
|
2008-03-03 |
2013-05-08 |
Dyax Corp |
Metalloproteinase 9 binding proteins
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US8075885B2
(en)
|
2008-04-07 |
2011-12-13 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating heart failure using an anti-GM-CSF antibody
|
|
US8314213B2
(en)
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
JP5646457B2
(en)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2009154026A1
(en)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
Antibody against calcified globule and use of the same
|
|
WO2010002862A2
(en)
|
2008-07-01 |
2010-01-07 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (fgfr3) binding proteins
|
|
EP2313109A2
(en)
|
2008-07-02 |
2011-04-27 |
Emergent Product Development Seattle, LLC |
Il6 immunotherapeutics
|
|
EP3009449B1
(en)
|
2008-07-16 |
2018-06-06 |
Institute for Research in Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
JP5841332B2
(en)
|
2008-07-18 |
2016-01-13 |
国立大学法人名古屋大学 |
Cell growth inhibitor
|
|
AU2009275889A1
(en)
|
2008-07-31 |
2010-02-04 |
Basf Plant Science Gmbh |
Plants having modified growth characteristics and a method for making the same
|
|
NZ591098A
(en)
|
2008-08-20 |
2012-08-31 |
Centocor Ortho Biotech Inc |
Engineered anti-il-13 antibodies, compositions, methods and uses
|
|
WO2010060186A1
(en)
|
2008-11-03 |
2010-06-03 |
Alethia Biotherapeutics Inc. |
Antibodies that specifically block the biological activity of a tumor antigen
|
|
US8183346B2
(en)
|
2008-12-05 |
2012-05-22 |
Eli Lilly And Company |
Anti-ferroportin 1 monoclonal antibodies and uses thereof
|
|
WO2010083179A2
(en)
|
2009-01-16 |
2010-07-22 |
Monsanto Technology Llc |
Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
|
|
US8673307B1
(en)
|
2009-03-09 |
2014-03-18 |
The Rockefeller University |
HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
|
|
WO2010107752A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
CA2756186A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
PE20120553A1
(en)
|
2009-03-25 |
2012-05-18 |
Genentech Inc |
ANTI-FGFR3 ANTIBODIES
|
|
US8722046B2
(en)
|
2009-04-08 |
2014-05-13 |
The United States Of America As Represented By The Secretary Of The Army |
Human monoclonal antibodies protective against bubonic plague
|
|
WO2010119704A1
(en)
|
2009-04-17 |
2010-10-21 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
|
EP2421899B1
(en)
*
|
2009-04-23 |
2016-06-08 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-human ror1 antibodies
|
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
JP5762408B2
(en)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
Antibodies against human respiratory syncytial virus (RSV) and methods of use
|
|
BR112012004387A2
(en)
|
2009-08-28 |
2015-09-08 |
Vlst Corp |
anticin antibodies that bind to multiple cc chemokines.
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
WO2011038290A2
(en)
|
2009-09-25 |
2011-03-31 |
The U. S. A., As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
WO2011047146A2
(en)
|
2009-10-14 |
2011-04-21 |
Centocor Ortho Biotech Inc. |
Methods of affinity maturing antibodies
|
|
JP5756757B2
(en)
|
2009-10-30 |
2015-07-29 |
東レ株式会社 |
Antibody having inhibitory activity against hepatitis C virus (HCV) and use thereof
|
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
|
HRP20171749T1
(en)
|
2009-11-11 |
2018-01-26 |
Ganymed Pharmaceuticals Gmbh |
Antibodies specific for claudin 6 (cldn6)
|
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
WO2011079902A2
(en)
|
2009-12-18 |
2011-07-07 |
Biolnvent International Ab |
Biological materials and uses thereof
|
|
AU2011215685B2
(en)
|
2010-02-12 |
2015-08-20 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
CN102884084B
(en)
|
2010-03-04 |
2016-12-07 |
西福根有限公司 |
Anti-HER 2 and compositions
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
US8468130B2
(en)
|
2010-04-02 |
2013-06-18 |
Skyfire Labs, Inc. |
Assisted hybrid mobile browser
|
|
EP2556085A2
(en)
|
2010-04-05 |
2013-02-13 |
Bar-Ilan University |
Protease-activatable pore-forming polypeptides
|
|
EP2572203B1
(en)
|
2010-05-17 |
2017-10-25 |
The Board of Regents of The University of Texas System |
Determination of antigen-specific antibody sequences in blood circulation
|
|
JO3330B1
(en)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
Cgrp antibodies
|
|
JP2012021943A
(en)
|
2010-07-16 |
2012-02-02 |
National Cancer Center |
Method for inspecting uterine cancer, test drug for uterine cancer and antibody for uterine cancer antigen
|
|
WO2012012695A2
(en)
|
2010-07-23 |
2012-01-26 |
Fred Hutchinson Cancer Research Center |
A method for the treatment of obesity
|
|
EP2619228A1
(en)
|
2010-09-22 |
2013-07-31 |
Novo Nordisk A/S |
Therapeutic factor viii antibodies
|
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
CA2815277A1
(en)
|
2010-10-29 |
2012-05-03 |
Immunogen, Inc. |
Novel egfr-binding molecules and immunoconjugates thereof
|
|
JO3756B1
(en)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
Human antibodies to the glucagon receptor
|
|
EP2455403A1
(en)
|
2010-11-23 |
2012-05-23 |
Pierre Fabre Medicament |
Homogeneous humanized antibodies against JAM-A that inhibit proliferation
|
|
EP2646469B1
(en)
*
|
2010-12-01 |
2017-11-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Chimeric rabbit/human ror1 antibodies
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
IL269565B2
(en)
|
2011-01-06 |
2024-06-01 |
Dyax Corp |
KALLIKREIN PLASMA BINDING PROTEINS
|
|
CA3027071A1
(en)
*
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
US8916160B2
(en)
|
2011-02-14 |
2014-12-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
|
HUE047085T2
(en)
|
2011-04-22 |
2020-04-28 |
Wyeth Llc |
Preparations and methods related to the Clostridium difficile mutant toxin
|
|
AU2012258087B2
(en)
|
2011-05-13 |
2017-07-20 |
Astellas Pharma Inc. |
Antibodies for treatment of cancer expressing claudin 6
|
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
|
US9102724B2
(en)
|
2011-08-12 |
2015-08-11 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
|
DK3485903T5
(en)
|
2011-09-23 |
2024-09-02 |
Mereo Biopharma 5 Inc |
VEGF/DLL4 BINDING AGENTS AND USES THEREOF
|
|
SMT202000091T1
(en)
|
2011-10-13 |
2020-05-08 |
Bristol Myers Squibb Co |
Antibody polypeptides that antagonize cd40l
|
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
|
EP2617319A1
(en)
|
2012-01-17 |
2013-07-24 |
Braun GmbH |
Head portion and handle portion of an oral care device
|
|
PT2818483T
(en)
|
2012-02-21 |
2017-10-09 |
Toray Industries |
Medicinal composition for treating and/or preventing cancer
|
|
RU2632645C2
(en)
|
2012-02-21 |
2017-10-06 |
Торэй Индастриз, Инк. |
Pharmaceutical composition for cancer treatment and/or prevention
|
|
ES2812849T3
(en)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and procedures for using them
|
|
EP2832856A4
(en)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
Anti-lamp5 antibody and utilization thereof
|
|
HUE036425T2
(en)
|
2012-03-30 |
2018-07-30 |
Toray Industries |
Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
|
|
PL2832365T3
(en)
|
2012-03-30 |
2018-04-30 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of liver cancer
|
|
WO2013152020A1
(en)
|
2012-04-03 |
2013-10-10 |
Novelmed Therapeutics, Inc. |
Humanized and chimeric anti-factor bb antibodies and uses thereof
|
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
EP2849789A4
(en)
|
2012-05-14 |
2016-02-24 |
Hoffmann La Roche |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
|
|
CN103421113B
(en)
|
2012-05-22 |
2018-01-19 |
武汉华鑫康源生物医药有限公司 |
Anti- BLyS antibody
|
|
JO3462B1
(en)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
Human Antibodies to GFR?3 and methods of use thereof
|
|
ES2702315T3
(en)
|
2012-08-24 |
2019-02-28 |
Univ California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
CN103792364B
(en)
|
2012-10-31 |
2016-06-08 |
张宝弘 |
For detecting reagent and the application thereof of circulating tumor cell ROR1 albumen in peripheral blood
|
|
TWI745610B
(en)
|
2012-11-14 |
2021-11-11 |
美商再生元醫藥公司 |
Recombinant cell surface capture proteins
|
|
ES2731681T3
(en)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Anti-DLL3 and PBD antibody conjugates and uses thereof
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
WO2014174111A1
(en)
|
2013-04-26 |
2014-10-30 |
Pierre Fabre Medicament |
Axl antibody-drug conjugate and its use for the treatment of cancer
|
|
PH12021550015A1
(en)
|
2013-05-20 |
2022-05-11 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
CN105873612A
(en)
|
2013-08-28 |
2016-08-17 |
施特姆森特克斯股份有限公司 |
Modified anti-DLL3 conjugates and methods of use
|
|
RU2016122041A
(en)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION
|
|
JP6174811B2
(en)
|
2013-12-11 |
2017-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Methods and compositions for targeted genomic modification
|
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
|
CN112390883A
(en)
|
2013-12-17 |
2021-02-23 |
基因泰克公司 |
anti-CD 3 antibodies and methods of use
|
|
JP2017502023A
(en)
|
2013-12-24 |
2017-01-19 |
ノーベルメッド セラピューティクス インコーポレイテッド． |
Compositions and methods for treating eye diseases
|
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
DK3708579T3
(en)
|
2014-04-01 |
2024-07-22 |
Biontech Cell & Gene Therapies Gmbh |
CLAUDIN-6-SPECIFIC IMMUNE RECEPTORS AND T-CELL EPITOPES
|
|
BR112016024363A2
(en)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
antibody-drug conjugate and its use for cancer treatment
|